## CACHE Challenge #1 - Experimental Validation Preliminary Results

March 21<sup>st</sup> 2023

# The Challenge

- CACHE participants were asked to use their computational methods to predict ligands binding the central cavity of the WDR domain of LRRK2. There is so far no known molecule for this binding site. <u>See details</u>
- After a double-blind peer review where each applicant reviewed 5 applications, 23 participants joined the challenge, representing a diverse array of physics-based and AI <u>computational methods</u>.
- Participants collectively selected 1955 compounds (no more than 100 compounds per participant) that we ordered and received from Enamine.
- All experimental data, the structure of the compounds and their associated computational methods will be publicly released at the end of this Challenge.

# **Experimental Validation**

- Compounds were first screened at 50  $\mu$ M and 100  $\mu$ M in a surface plasmon resonance (SPR) binding assay where biotinylated LRRK2-WDR was captured on a streptavidin chip.
- >200 compounds with a binding signal between 50% and 200% of the expected value were cherry picked for doseresponse experiment in the same assay



- 73 compounds from 18 participants produced a dose response and measurable  $K_D$  below 150  $\mu$ M and were selected for hit expansion, where participants can select up to 50 follow-up compounds for experimental characterization.
- <u>The hit expansion round will be critical to build confidence in these 73 hit candidates</u>. We expect that progressable hits will produce a clear structure-activity relationship (SAR).

Some of the predicted molecules produced promising data across multiple assays. We hope the hit-expansion round will generate convincing SAR.



Some of the predicted molecules produced promising data across multiple assays. We hope the hit-expansion round will generate convincing SAR.



### ACKNOWLEDGEMENTS



## **I**SGC

CACHE #1 Experimental Platform: Structural Genomics Consortium, University of Toronto

Matthieu Schapira Fengling Li Suzanne Ackloo Sumera Perveen Irene Chau Levon Halabelian Serah Kimani Shabbir Ahmad Pegah Ghiabi Elisa Gibson Carla Kharadjian Almagul Seitova Helen Li Maria Kutera Albina Bolotokova Rachel Harding











#### www.thesgc.org

FUNDING PARTNERS

The Structural Genomics Consortium is a registered charity (no: 1097737) that receives funds from Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Genome Canada through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510], Janssen, Merck KGaA (aka EMD in Canada and US), Pfizer and Takeda.